Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
|
IN |
|
M
|
MEGAIN Holding (Cayman) Co Ltd
HKEX:6939
|
CN |
|
Alps Alpine Co Ltd
TSE:6770
|
JP |
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The firm offers products, such as tablets, capsules, liquid injection, cream in tubes, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The firm offers products, such as tablets, capsules, liquid injection, cream in tubes, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
Strong Q3 Performance: Lincoln Pharmaceuticals reported Q3 revenue of INR 166.32 crores, up from INR 146.55 crores a year ago, with solid gains across profit metrics.
Profit Growth: Net profit for the quarter rose to INR 28.60 crores from INR 20.77 crores last year; EPS increased to INR 14.28 from INR 10.37.
Cepha Block Progress: The new cephalosporin block has commenced operations and is expected to bring in INR 45 crores in revenue this year, having already achieved breakeven.
Export Focus: Exports contribute about 70% of revenue, with Africa making up around 40% of exports and Canada and regulated markets seeing ramp-ups through CDMO/CMO projects.
Growth Ambition: The company maintains its INR 1,000 crore revenue target by FY '28, with expansion expected in both domestic and export markets, though timing may be delayed by up to six months.
Margin Outlook: EBITDA margins are expected to remain in the 15–18% range, with possible improvement as the business mix evolves.
R&D Investment: R&D expenses are currently 1.8–2% of revenue, with plans to step up to 3–3.25% as the company invests in regulated market opportunities.
Dividend Policy: Management is evaluating higher dividends but may prioritize inorganic growth or new facilities over increased payouts.
